Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix, MRM Proteomics Partner on Lung Cancer Assays

NEW YORK (GenomeWeb) – MRM and Biodesix said today that they are partnering to develop mass spectrometry-based assays for lung cancer.

Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI technologies to develop blood-based tests for lung cancer.

MRM's iMALDI method uses upfront enrichment of target proteins followed by MALDI mass spec analysis of those proteins.

"Examining a patient’s genomic data has advanced targeted therapies. However, proteins are the targets of most drugs and hold the key to unlocking the promise of precision medicine," Christoph Borchers, CSO for MRM Proteomics, said in a statement. "Biodesix is a natural partner for our proteomic technology because they are committed to a multi-omics approach to reveal a more complete molecular profile of lung cancer in the body. We believe that this partnership will produce much-needed advances in the proteomic space and lead to more precise lung cancer diagnostic tools that can help guide treatment decisions."

"Elevating the importance of proteomics in revealing the full complexity of cancer is critical to getting patients the right treatment at the right time. MRM Proteomics is a leader in providing technologies that can help us unleash this potential," said Scott Hutton, COO for Biodesix.

Financial and other terms of the agreement were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.